Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle

Journal of Hepatology

Volumn 52, Issue 5, 2010, Pages 771-775

  Bhoori, Sherrie ^a   Toffanin, Sara ^a,b   Sposito, Carlo ^a   Germini, Alessandro ^a   Pellegrinelli, Alessandro ^a   Lampis, Andrea ^a   Mazzaferro, Vincenzo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Everolimus; Hepatocellular carcinoma; Liver transplantation; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; BETA CATENIN; CYCLOSPORIN; EVEROLIMUS; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN S6; RAS PROTEIN; RIBAVIRIN; SORAFENIB; VIRUS RNA; WNT PROTEIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CASE REPORT; CHEMOEMBOLIZATION; DRUG WITHDRAWAL; FATTY LIVER; GRAFT INFECTION; HAND FOOT SYNDROME; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MICROSATELLITE MARKER; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; RECURRENT CANCER; SIGNAL TRANSDUCTION; STOMACH HEMORRHAGE; VIRUS LOAD;

ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BENZENESULFONATES; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DNA MUTATIONAL ANALYSIS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIVIDUALIZED MEDICINE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POINT MUTATION; PYRIDINES; RIBAVIRIN; SIROLIMUS;

EID: 77951620565     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.01.025     Document Type: Article

References (27)

1. Aravalli R.N., Steer C.J., and Cressman E.N. Molecular mechanisms of hepatocellular carcinoma. Hepatology 48 (2008) 2047-2063
2. Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol 44 (2009) 136-141
3. Chiang D.Y., Villanueva A., Hoshida Y., Peix J., Newell P., Minguez B., et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68 (2008) 6779-6788
4. Bioulac-Sage P., Rebouissou S., Thomas C., Blanc J.F., Saric J., Sa Cunha A., et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 46 (2007) 740-748
5. Villanueva A., Toffanin S., and Llovet J.M. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol 20 (2008) 444-453
6. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
7. Edmondson H.A., and Steiner P.E. Primary carcinoma of the liver: a study of 100 cases among 48, 900 necropsies. Cancer 7 (1954) 462-503
8. International Consensus Group for Hepatocellular Neoplasia. The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658-64.
9. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
10. Bedossa P., and Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The Metavir Cooperative Study Group. Hepatology 24 (1996) 289-293
11. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf [accessed on 10.01.09].
12. Signoroni S., Frattini M., Negri T., Pastore E., Tamborini E., Casieri P., et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res. 13 (2007) 5034-5040 Erratum in: Clin Cancer Res. 2008;14:4354
13. Villanueva A., Chiang D.Y., Newell P., Peix J., Thung S., Alsinet C., et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135 (2008) 1972-1983
14. Newell P., Toffanin S., Villanueva A., Chiang D.Y., Minguez B., Cabellos L., et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 51 (2009) 725-733
15. Llovet J.M., Di Bisceglie A.M., Bruix J., Kramer B.S., Lencioni R., Zhu A.X., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100 (2008) 698-711
16. Boyault S., Rickman D.S., De Reyniès A., Balabaud C., Rebouissou S., Jeannot E., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45 (2007) 42-52
17. Takigawa Y., and Brown A.M. Wnt signaling in liver cancer. Curr Drug Targets 9 (2008) 1013-1024
18. Schreibman I.R., Bejarano P., Martinez E.J., and Regev A. Very late recurrence of hepatocellular carcinoma after liver transplantation: case report and literature review. Transplant Proc 38 (2006) 3140-3143
19. Chiba T., Kamiya A., Yokosuka O., and Iwama A. Cancer stem cells in hepatocellular carcinoma: recent progress and perspective. Cancer Lett 286 (2009) 145-153
20. Dhillon A.S., Hagan S., Rath O., and Kolch W. MAP kinase signalling pathways in cancer. Oncogene 26 (2007) 3279-3290
21. Zhang Z., Zhou X., Shen H., Wang D., and Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med 7 (2009) 40-52
22. Vinciguerra M., Sgroi A., Veyrat-Durebex C., Rubbia-Brandt L., Buhler L.H., and Foti M. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 49 (2009) 1176-1184
23. Semela D., Piguet A.C., Kolev M., Schmitter K., Hlushchuk R., Djonov V., et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 46 (2007) 840-848
24. Wang Z., Zhou J., Fan J., Qiu S.J., Yu Y., Huang X.W., et al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 14 (2008) 5124-5130
25. Carracedo A., Baselga J., and Pandolfi P.P. Deconstruction feed-back signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 7 (2008) 3805-3809
26. Piguet A.C., Semela D., Keogh A., Wilkens L., Stroka D., Stoupis C., et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 49 (2008) 78-87
27. Huynh H., Chow P.K., Palanisamy N., Salto-Tellez M., Goh B.C., Lee C.K., et al. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol 49 (2008) 52-60